ロード中...
Gabapentin Enacarbil Extended‐Release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial
BACKGROUND: We reanalyzed a multisite 26‐week randomized double‐blind placebo‐controlled clinical trial of 600 mg twice‐a‐day Gabapentin Enacarbil Extended‐Release (GE‐XR), a gabapentin prodrug, designed to evaluate safety and efficacy for treating alcohol use disorder. In the original analysis (n =...
保存先:
| 出版年: | Alcohol Clin Exp Res |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540534/ https://ncbi.nlm.nih.gov/pubmed/33460198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/acer.14414 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|